644982-55-8

Basic information

• Product Name: 3-Bromo-5-cyanobenzaldehyde
• Synonyms: 3-Bromo-5-cyanobenzaldehyde;3-broMo-5-forMylbenzonitrile
• CAS NO: 644982-55-8
• Molecular Formula: C₈H₄BrNO
• Molecular Weight: 210.04
• Mol File: 644982-55-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-Bromo-5-cyanobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-cyanobenzaldehyde(644982-55-8)
• EPA Substance Registry System: 3-Bromo-5-cyanobenzaldehyde(644982-55-8)

Safety Data

• Hazardous Substances Data: 644982-55-8(Hazardous Substances Data)

Usage

Uses

3-Bromo-5-formylbenzonitrile is used to prepare substituted (homo)piperidines as NK1 receptor ligands.

Upstream product

• 56990-02-4 3,5-dibromobenzaldehyde 
• 24964-64-5 3-Cyanobenzaldehyde 
• 1205515-06-5 3-bromo-5-(hydroxymethyl)benzonitrile 
• 919347-53-8 3-bromo-5-formylbenzamide 
• 97165-77-0 3,5-dibromobenzonitrile 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 644982-56-9 3-bromo-5-(methylamino)benzonitrile 
• 1201403-02-2 5-(3-cyano-5-formylphenyl)-3-[1-(ethylsulfonyl)-4-piperidinyl]-1H-indole-7-carboxamide 

Relevant articles and documents

HETEROCYCLIC AMIDE COMPOUND

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula

PYRIDONE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

The present invention relates to 2-pyridone derivatives of Formula (I) or (IV) as herein described, compositions containing such compounds, synthetic processes for making such compounds, and therapeutic methods that include the administration of such comp

CHEMICAL COMPOUNDS

The present invention relates to cyclic amine derivatives of formula(I) (I)whereinR represents halogen, C1-4 alkyl, cyano, C1-4 alkoxy, trifluoromethyl or trifluoromethoxy;R1 represents hydrogen, halogen, C3-7cycloalkyl, hydroxy, nitro, cyano or C1-4 alkyl optionally substituted by halogen, cyano or C1-4 alkoxy;R2 represents hydrogen or C1-4 alkyl;R3 and R4 independently represent hydrogen, cyano, C1-4 alkyl or R3 together with R4 represents C3-7 cycloalkyl;R5 represents trifluoromethyl, S(O)t C 1-4 alkyl, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy, halogen or cyano;R6 represents hydrogen or (CH2)rR7;R7 represents hydrogen, C3-7 cycloalkyl, NH(C1-4alkylOC1-4alkoxy), NH(C1-4alkyl), N(C1-4alkyl)2, OC(O)NR9R8, NR8C(O)R9 or C(O)NR9R8;R9 and R8 independently represent hydrogen, C1-4 alkyl or C3-7 cycloalkyl; m represents zero or an integer from 1 to 4;n represents 1 or 2;p is zero or an integer from 1 to 3;q is an integer from 1 to 3;r is an integer from 1 to 4;t is 0, 1 or 2;provided that when m is 0, p is 2, q, r and n represent 1, R1, R2,R3, R4, R5 and R7 are hydrogen and R is chlorine, R5 is not iodine; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of serotonin reuptake transporter protein.